CellTran, York Pharma deal

York acquired the marketed products, clinical pipeline and manufacturing facilities of fellow dermatology company CellTran for £70,000 ($108,000) in cash, plus the greater of £100,000 ($154,000) or 10% royalties on sales of Cell Tran's marketed wound and burn products based on keratinocytes, Myskin and Cryoskin. Pipeline products include Lyphoderm, a freeze-dried total lysate from keratinocytes that has completed a Phase II trial to treat venous leg ulcers, and Ulcodress, a hydrogel wound dressing for which the company will seek CE Mark approval in Europe. CellTran entered administration on May 30. ...